Clinical Trial Update: Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease

View source ↗

Summary

Columbia University led a study investigating novel mediators of lipodystrophy and metabolic consequences in Cushing's syndrome. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cushing Syndrome

Snippet

Sponsor: Columbia University | Conditions: Cushing's Syndrome | Status: COMPLETED